TY - JOUR
T1 - Free-water imaging of the hippocampus is a sensitive marker of Alzheimer's disease
AU - for the Alzheimer's Disease Neuroimaging Initiative
AU - Ofori, Edward
AU - DeKosky, Steven T.
AU - Febo, Marcelo
AU - Colon-Perez, Luis
AU - Chakrabarty, Paramita
AU - Duara, Ranjan
AU - Adjouadi, Malek
AU - Golde, Todd E.
AU - Vaillancourt, David E.
N1 - Publisher Copyright:
© 2019
PY - 2019
Y1 - 2019
N2 - Validating sensitive markers of hippocampal degeneration is fundamental for understanding neurodegenerative conditions such as Alzheimer's disease. In this paper, we test the hypothesis that free-water in the hippocampus will be more sensitive to early stages of cognitive decline than hippocampal volume, and that free-water in hippocampus will increase across distinct clinical stages of Alzheimer's disease. We examined two separate cohorts (N = 126; N = 112) of cognitively normal controls, early and late mild cognitive impairment (MCI), and Alzheimer's disease. Demographic, clinical, diffusion-weighted and T1-weighted imaging, and positron emission tomography (PET) imaging were assessed. Results indicated elevated hippocampal free-water in early MCI individuals compared to controls across both cohorts. In contrast, there was no difference in volume of these regions between controls and early MCI. ADNI free-water values in the hippocampus was associated with low CSF AB1–42 levels and high global amyloid PET values. Free-water imaging of the hippocampus can serve as an early stage marker for AD and provides a complementary measure of AD neurodegeneration using non-invasive imaging.
AB - Validating sensitive markers of hippocampal degeneration is fundamental for understanding neurodegenerative conditions such as Alzheimer's disease. In this paper, we test the hypothesis that free-water in the hippocampus will be more sensitive to early stages of cognitive decline than hippocampal volume, and that free-water in hippocampus will increase across distinct clinical stages of Alzheimer's disease. We examined two separate cohorts (N = 126; N = 112) of cognitively normal controls, early and late mild cognitive impairment (MCI), and Alzheimer's disease. Demographic, clinical, diffusion-weighted and T1-weighted imaging, and positron emission tomography (PET) imaging were assessed. Results indicated elevated hippocampal free-water in early MCI individuals compared to controls across both cohorts. In contrast, there was no difference in volume of these regions between controls and early MCI. ADNI free-water values in the hippocampus was associated with low CSF AB1–42 levels and high global amyloid PET values. Free-water imaging of the hippocampus can serve as an early stage marker for AD and provides a complementary measure of AD neurodegeneration using non-invasive imaging.
KW - Free-water imaging
KW - Hippocampus
KW - Mild cognitive impairment
KW - Neurodegeneration
UR - http://www.scopus.com/inward/record.url?scp=85071395246&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071395246&partnerID=8YFLogxK
U2 - 10.1016/j.nicl.2019.101985
DO - 10.1016/j.nicl.2019.101985
M3 - Article
C2 - 31470214
AN - SCOPUS:85071395246
SN - 2213-1582
VL - 24
JO - NeuroImage: Clinical
JF - NeuroImage: Clinical
M1 - 101985
ER -